Michael Barbella, Managing Editor08.27.22
Not surprisingly, ODT's Top Companies report was among the top-read stories this past week on the magazine's website.
For the second consecutive week, the annual ranking of the orthopedic industry's 10 most lucrative companies garnered significant page views, as did a companion feature on six up-and-coming firms with promising technologies. Those companies included CoreBone, GreenBone Ortho SpA, Ossio, Fundamental Surgery, Onkos Surgical, and Extremity Medical.
Topping the Top Companies report, however, (an impressive feat, given the popularity of the ranking) was a feature (July-August issue) on additive manufacturing at the point of care (POC). Freelance writer Mark Crawford outlined the ways that 3D printing is being used in the industry to improve outcomes, increase efficiency, and reduce total costs; The primary use case for POC AM/3DP (point of care additive manufacturing/3D printing) today is creating physical anatomical patient models, especially for patients with complex or rare conditions. Physicians analyze these models to determine the best treatment options, prepare for surgery, or explain procedures to patients—allowing them to make better-informed decisions that lead to improved patient outcomes. "Physicians analyze these models to determine the best treatment options, prepare for surgery, or explain procedures to patients—allowing them to make better-informed decisions that lead to improved patient outcomes," Crawford writes.
Other items of interest this past week were an FDA approval for Abbott and Axxcess Capital Partners LLC's investment in Subchondral Solutions.
Abbott received FDA approval for its next-gen Proclaim Plus spinal cord stimulation (SCS) system with proprietary FlexBurst360 therapy. FlexBurst360 therapy is the newest generation of Abbott’s BurstBR stimulation, with pain coverage across up to six areas of the trunk and/or limbs. The therapy also allows programming to be adjusted as therapy needs evolve.
Subchondral Solutions, meanwhile, closed a Series C funding round led by Eli Spiro, CEO of Axxcess Capital Partners LLC. The company plans to use the money to expand its S-Core platform technology.
For the second consecutive week, the annual ranking of the orthopedic industry's 10 most lucrative companies garnered significant page views, as did a companion feature on six up-and-coming firms with promising technologies. Those companies included CoreBone, GreenBone Ortho SpA, Ossio, Fundamental Surgery, Onkos Surgical, and Extremity Medical.
Topping the Top Companies report, however, (an impressive feat, given the popularity of the ranking) was a feature (July-August issue) on additive manufacturing at the point of care (POC). Freelance writer Mark Crawford outlined the ways that 3D printing is being used in the industry to improve outcomes, increase efficiency, and reduce total costs; The primary use case for POC AM/3DP (point of care additive manufacturing/3D printing) today is creating physical anatomical patient models, especially for patients with complex or rare conditions. Physicians analyze these models to determine the best treatment options, prepare for surgery, or explain procedures to patients—allowing them to make better-informed decisions that lead to improved patient outcomes. "Physicians analyze these models to determine the best treatment options, prepare for surgery, or explain procedures to patients—allowing them to make better-informed decisions that lead to improved patient outcomes," Crawford writes.
Other items of interest this past week were an FDA approval for Abbott and Axxcess Capital Partners LLC's investment in Subchondral Solutions.
Abbott received FDA approval for its next-gen Proclaim Plus spinal cord stimulation (SCS) system with proprietary FlexBurst360 therapy. FlexBurst360 therapy is the newest generation of Abbott’s BurstBR stimulation, with pain coverage across up to six areas of the trunk and/or limbs. The therapy also allows programming to be adjusted as therapy needs evolve.
Subchondral Solutions, meanwhile, closed a Series C funding round led by Eli Spiro, CEO of Axxcess Capital Partners LLC. The company plans to use the money to expand its S-Core platform technology.